{"id":"NCT02742441","sponsor":"Therapeutics, Inc.","briefTitle":"A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06","primaryCompletion":"2017-02-27","completion":"2017-06-16","firstPosted":"2016-04-19","resultsPosted":"2018-11-14","lastUpdate":"2018-11-14"},"enrollment":409,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"122-0551 Foam","otherNames":[]},{"type":"DRUG","name":"Vehicle Foam","otherNames":[]}],"arms":[{"label":"122-0551 Foam","type":"EXPERIMENTAL"},{"label":"Vehicle Foam","type":"PLACEBO_COMPARATOR"}],"summary":"This Phase 3 study (Study 310) has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Subjects Rated a \"Treatment Success\" Based on the Investigator's Global Assessment (IGA)","timeFrame":"Day 15","effectByArm":[{"arm":"122-0551 Foam","deltaMin":30.7,"sd":null},{"arm":"Vehicle Foam","deltaMin":7.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":["31424709"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":205},"commonTop":["Headache","Application site pain","Application site pruritis","Blepharitis","Upper respiratory tract infection"]}}